Sagimet Biosciences Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
SGMT$10.89+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss (unaudited)
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except for share and per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses: | ||||
| Research and development | $11,535 | $7,248 | $18,530 | $22,590 |
| General and administrative | 4,283 | 4,677 | 9,001 | 9,200 |
| Total operating expenses | 15,818 | 11,925 | 27,531 | 31,790 |
| Loss from operations | (15,818) | (11,925) | (27,531) | (31,790) |
| Other income: | ||||
| Interest income and other, net | 1,865 | 1,539 | 2,928 | 3,228 |
| Total other income | 1,865 | 1,539 | 2,928 | 3,228 |
| Net loss | $(13,953) | $(10,386) | $(24,603) | $(28,562) |
| Net loss per share of Series A and Series B common stock outstanding, basic and diluted | $(0.26) | $(0.32) | $(0.57) | $(0.89) |
| Weighted-average shares of Series A and Series B common stock outstanding, basic and diluted | 53,114,533 | 32,195,366 | 42,893,900 | 32,195,355 |
| Net loss | $(13,953) | $(10,386) | $(24,603) | $(28,562) |
| Other comprehensive loss: | ||||
| Net unrealized loss on marketable securities | (85) | (45) | (197) | (154) |
| Total comprehensive loss | $(14,038) | $(10,431) | $(24,800) | $(28,716) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.